Lorenza Landi
Overview
Explore the profile of Lorenza Landi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
2.
Cappuzzo F, Ricciuti B, Delmonte A, Bonanno L, Wang X, Lye W, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836372
Background: The role of activating alterations in the MAPK pathway in predicting immunotherapy efficacy in lung squamous cell carcinoma (LSCC) patients is largely unknown. The aims of the randomized, phase...
3.
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Normanno N, Morabito A, Rachiglio A, Sforza V, Landi L, Bria E, et al.
Nat Rev Clin Oncol
. 2025 Jan;
22(3):215-231.
PMID: 39833354
Circulating tumour DNA (ctDNA) can be released by cancer cells into biological fluids through apoptosis, necrosis or active release. In patients with non-small-cell lung cancer (NSCLC), ctDNA levels correlate with...
4.
Mariotti S, Minuti G, Landi L, Bria E, Carlucci G, Di Salvatore M, et al.
Heliyon
. 2024 Dec;
10(23):e39324.
PMID: 39687089
Small-Cell Lung Cancer (SCLC) accounts for 15 % of all lung cancer cases. Due to comorbidities and its aggressive behaviour, patients are highly symptomatic even at a non-metastatic stage. Standardizing...
5.
La Salvia A, Meyer M, Hirsch F, Kerr K, Landi L, Tsao M, et al.
Crit Rev Oncol Hematol
. 2024 May;
200:104401.
PMID: 38815876
Several observations indicate that protein expression analysis by immunohistochemistry (IHC) remains relevant in individuals with non-small-cell lung cancer (NSCLC) when considering targeted therapy, as an early step in diagnosis and...
6.
Marinelli D, Gallina F, Pannunzio S, Di Civita M, Torchia A, Giusti R, et al.
Crit Rev Oncol Hematol
. 2023 Oct;
192:104190.
PMID: 37871779
The use of neoadjuvant or perioperative anti-PD(L)1 was recently tested in multiple clinical trials. We performed a systematic review and meta-analysis of randomised trials comparing neoadjuvant or perioperative chemoimmunotherapy to...
7.
Giacomini P, Valenti F, Allegretti M, Pallocca M, De Nicola F, Ciuffreda L, et al.
J Transl Med
. 2023 Oct;
21(1):725.
PMID: 37845764
Background: Molecular Tumor Boards (MTB) operating in real-world have generated limited consensus on good practices for accrual, actionable alteration mapping, and outcome metrics. These topics are addressed herein in 124...
8.
Orciuolo C, Cappuzzo F, Landi L, Resuli B, Carpano S, Vidiri A, et al.
JTO Clin Res Rep
. 2023 Aug;
4(8):100545.
PMID: 37533438
Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a...
9.
Di Lisa F, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, et al.
Front Oncol
. 2023 Jun;
13:1152123.
PMID: 37260975
Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine,...
10.
Gallina F, Taje R, Cecere F, Forcella D, Landi L, Minuti G, et al.
Lung Cancer
. 2023 May;
180:107215.
PMID: 37126920
Objectives: Despite notable advances made in preoperative staging, unexpected nodal metastases after surgery are still significantly detected. Given the promising role of neoadjuvant targeted treatments, the definition of novel predictive...